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ABSTRACT
Background
The extent to which diabetes mellitus or hyperglycemia is related to risk of death 
from cancer or other nonvascular conditions is uncertain.
Methods
We calculated hazard ratios for cause-specific death, according to baseline diabetes 
status or fasting glucose level, from individual-participant data on 123,205 deaths 
among 820,900 people in 97 prospective studies.
Results
After adjustment for age, sex, smoking status, and body-mass index, hazard ratios 
among persons with diabetes as compared with persons without diabetes were as 
follows: 1.80 (95% confidence interval [CI], 1.71 to 1.90) for death from any cause, 
1.25 (95% CI, 1.19 to 1.31) for death from cancer, 2.32 (95% CI, 2.11 to 2.56) for 
death from vascular causes, and 1.73 (95% CI, 1.62 to 1.85) for death from other 
causes. Diabetes (vs. no diabetes) was moderately associated with death from can-
cers of the liver, pancreas, ovary, colorectum, lung, bladder, and breast. Aside from 
cancer and vascular disease, diabetes (vs. no diabetes) was also associated with 
death from renal disease, liver disease, pneumonia and other infectious diseases, 
mental disorders, nonhepatic digestive diseases, external causes, intentional self-
harm, nervous-system disorders, and chronic obstructive pulmonary disease. Haz-
ard ratios were appreciably reduced after further adjustment for glycemia measures, 
but not after adjustment for systolic blood pressure, lipid levels, inflammation or 
renal markers. Fasting glucose levels exceeding 100 mg per deciliter (5.6 mmol per 
liter), but not levels of 70 to 100 mg per deciliter (3.9 to 5.6 mmol per liter), were 
associated with death. A 50-year-old with diabetes died, on average, 6 years earlier 
than a counterpart without diabetes, with about 40% of the difference in survival 
attributable to excess nonvascular deaths.
Conclusions
In addition to vascular disease, diabetes is associated with substantial premature 
death from several cancers, infectious diseases, external causes, intentional self-
harm, and degenerative disorders, independent of several major risk factors. (Funded 
by the British Heart Foundation and others.)
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The presence of diabetes mellitus  approximately doubles the risk of a wide range of vascular diseases.1 Evidence is also 
emerging that diabetes is associated with non-
vascular conditions, including positive associa-
tions with certain cancers (e.g., liver cancer) and 
negative associations with other cancers (e.g., 
prostate cancer).2-4 However, a joint consensus 
statement of the American Diabetes Association 
and the American Cancer Society indicated that it 
is unclear whether such associations are direct 
(e.g., due to hyperglycemia) or indirect (e.g., due to 
diabetes as a marker of underlying biologic fac-
tors such as insulin resistance or hyperinsu-
linemia that alter the risk of cancer) or due to 
shared risk factors (e.g., obesity) or a combination 
of these.5-8 Furthermore, many previous reports 
have considered diabetes in relation to only one 
or a few selected cancers or other nonvascular 
conditions. Since diabetes is a multisystem disor-
der, there is a need for adequately powered, stan-
dardized assessment of associations of diabetes 
with the risk of death from a broad range of 
causes.9,10
We aimed to provide reliable estimates of any 
independent associations of baseline diabetes and 
fasting blood glucose level with the risk of cause-
specific death by analyzing data from 820,900 
people who were at risk for a total of 12.3 mil-
lion person-years. We also estimated the effect of 
diabetes on life expectancy in adults.
Methods
The study was designed and conducted by the 
independent academic coordinating center of the 
Emerging Risk Factors Collaboration (ERFC). 
Members of the coordinating center vouch for 
the accuracy and completeness of the data, the 
data analysis, and the results and made the deci-
sion to submit the article for publication. The 
sponsors had no role in the design, analysis, or 
interpretation of the study. The study was ap-
proved by the Cambridgeshire Ethics Review 
Committee.
Details of the ERFC have been published pre-
viously11 (also see the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org). Specifically, we have already published 
reports on the associations of  lipids, lipoproteins, 
and inflammatory markers with the risk of vas-
cular disease and cause-specific death12-14 — the 
foregoing being risk factors that were the initial 
focus of the ERFC.11 In 2009, the ERFC agreed 
to extend analyses to diabetes and other meta-
bolic markers in relation to the risk of incident 
fatal and nonfatal vascular disease outcomes1 and 
cause-specific death (see the Supplementary Ap-
pendix). The current analyses focus on individual-
participant data from 97 prospective studies that 
had information about the diagnosis of diabetes 
or the fasting blood-glucose level at baseline, 
that did not select participants on the basis of 
having previous chronic disease (including vascu-
lar disease or diabetes), that included recording 
of cause-specific deaths classified according to 
clearly defined criteria, and that had accrued 
more than 1 year of follow-up data. Study details 
are presented in Table 1 in the Supplementary 
Appendix (with references also listed). There were 
820,900 participants who had no known preexist-
ing vascular disease at baseline and for whom 
there was complete information about age, sex, 
smoking status (current smoker vs. any other sta-
tus), body-mass index (BMI), history of diabetes 
or fasting glucose level (measured after ≥8 hours 
of fasting or overnight fasting), and subsequent 
cause-specific death recorded during follow-up. 
The contributing studies classified deaths accord-
ing to the primary cause (or, in its absence, the 
underlying cause), on the basis of coding from 
the International Classification of Diseases, revisions 
8 through 10, to at least three digits, or according 
to study-specific classification systems; ascertain-
ment was based on death certificates. Attribu-
tion of death refers to the primary cause provid-
ed. A total of 67 of the 97 contributing studies 
also used medical rec ords, findings on autopsy, 
and other supplementary sources to help classify 
deaths. We sought information on a range of risk 
factors and medication use at baseline (e.g., 
agents for lowering blood pressure, cholesterol, 
and glucose). Information on diabetes type (i.e., 
type 1 or 2) was generally not available, though 
the age of the participants suggests that the 
large majority with diabetes would have type 2.
Following the example of previous reports 
from the ERFC,12-15 we assessed whether base-
line diabetes status (ascertained on the basis of 
self-report, medication use, fasting glucose level 
≥126 mg per deciliter [7.0 mmol per liter], or a 
combination of these) and baseline fasting glu-
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cose level relate to death from any cause and its 
main components, including deaths from cancer, 
vascular disease, and nonvascular conditions not 
attributed to cancer, as well as to further subdivi-
sions of these outcomes (e.g., site-specific can-
cers) (see definitions in Table 2 in the Supple-
mentary Appendix).
Hazard ratios were calculated with the use 
of Cox proportional-hazards regression models 
stratified according to study, sex, and when ap-
propriate, trial group. To minimize potential 
bias, loge hazard ratios were calculated sepa-
rately within each study and then pooled across 
studies by means of a random-effects meta-
analysis.16 For the analyses of death from spe-
cific causes (cancer and noncancer, nonvascular), 
a one-step fixed-effect meta-analysis was used. 
We used methods described previously to charac-
terize shapes of associations with fasting glucose 
level and to investigate heterogeneity.1,16 Unless 
otherwise specified, hazard ratios were adjusted 
for baseline age, sex, smoking status, and BMI. 
In subsidiary analyses, hazard ratios were also 
adjusted for other characteristics.
We corrected for regression dilution in sub-
sidiary analyses, using serial measurements in 
331,515 participants (mean interval, 2.9 years).17 
Participants were included in analyses of death 
irrespective of the previous occurrence of non-
fatal events. For each specific cause of death, 
participants’ data were censored if the participant 
was lost to follow-up, died from other causes, or 
reached the end of the follow-up period. Esti-
mates of cumulative survival from 35 years of 
age and older among those with and those with-
out diabetes at baseline were calculated by apply-
ing hazard ratios (specific to age at risk and sex) 
for cause-specific mortality associated with dia-
betes to cause-specific rates of death at 35 years 
of age and older for residents of the European 
Union.18,19 The Supplementary Appendix provides 
further statistical details. Analyses were carried 
out with Stata software (release 11).
Results
Among the 820,900 participants included in 
analyses of diabetes status or fasting glucose 
level, the mean (±SD) age at baseline was 55±9 
years; 48% were women. The large majority of 
participants were enrolled in Europe (58%) or 
North America (36%). Of the 715,061 participants 
included in analyses of diabetes status, 40,116 
(6%) had diabetes at the time of enrollment (Ta-
ble 1). The baseline characteristics of participants 
included in the analyses of fasting glucose are 
listed in Table 3 in the Supplementary Appendix. 
During the 12.3 million person-years at risk (me-
dian time to death, 13.6 years), 123,205 deaths 
were recorded: 41,320 from cancer, 44,407 from 
vascular disease, 27,661 from other causes, and 
9817 of unknown or ill-defined cause (Table 4 in 
the Supplementary Appendix).
Diabetes and Mortality
The crude overall rates of death were higher among 
participants with diabetes than among those 
without diabetes: 29 per 1000 person-years ver-
sus 12 per 1000 person-years among men, respec-
tively, and 23 per 1000 person-years versus 7 per 
1000 person-years among women, respectively. 
The corresponding cause-specific rates of death 
were as follows: for cancer deaths, 7 versus 4 per 
1000 person-years among men and 4 versus 3 per 
1000 person-years among women; for vascular 
deaths, 13 versus 5 per 1000 person-years among 
men and 11 versus 2 per 1000 person-years among 
women; and for noncancer, nonvascular deaths, 
6 versus 3 per 1000 person-years among men and 
6 versus 2 per 1000 person-years among women.
Hazard ratios for death among participants 
with diabetes, as compared to those without 
diabetes, after adjustment for baseline age, sex, 
smoking status, and BMI, were as follows: 1.80 
(95% confidence interval [CI], 1.71 to 1.90) for 
death from any cause, 1.25 (95% CI, 1.19 to 1.31) 
for death from cancer, 2.32 (95% CI, 2.11 to 2.56) 
for death from vascular causes, 1.73 (95% CI, 
1.62 to 1.85) for death from nonvascular causes 
not attributed to cancer, and 1.88 (95% CI, 1.62 
to 2.18) for deaths of unknown or ill-defined 
cause (Fig. 1 in the Supplementary Appendix). 
These hazard ratios were not appreciably reduced 
after additional adjustment for systolic blood 
pressure, lipid levels, C-reactive protein levels, 
fibrinogen levels, alcohol use, estimated glomer-
ular filtration rate, or indicators of socioeco-
nomic status, when such information was avail-
able. However, the hazard ratios were reduced 
considerably after adjustment for fasting glucose 
or glycated hemoglobin levels (Table 2).
Hazard ratios for death among participants 
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with diabetes, as compared to those without dia-
betes, were significantly higher at younger ages 
and among women, except for death from any 
cancer (Fig. 2 in the Supplementary Appendix). 
Hazard ratios appeared to decline somewhat with 
increasing calendar decade of study enrollment 
(Fig. 3 in the Supplementary Appendix). Diabe-
tes was moderately associated with deaths from 
cancers of the liver, pancreas, ovary, colorectum, 
lung, bladder, and breast (Fig. 1A, and Fig. 4 in 
the Supplementary Appendix). Aside from cancer 
and vascular disease, diabetes was also associated 
with deaths from renal disease, liver disease, 
pneumonia, other infectious diseases, mental 
disorders, nonhepatic digestive diseases, exter-
nal causes, intentional self-harm, nervous system 
disorders, and chronic obstructive pulmonary 
disease (Fig. 1B).
Table 1. Baseline Data Used in Analyses of Diabetes and Cause-Specific Death, According to Participants’ Diabetes Status.*
Characteristic
Diabetes 
(N = 40,116)
No Diabetes 
(N = 674,945)
Demographic factors
Age — yr 58±8 55±8
Sex — no. (%)
Male 21,213 (53) 337,178 (50)
Female 18,903 (47) 337,767 (50)
Geographic region or country — no. (%)
North America 23,844 (59) 257,818 (38)
Europe 11,883 (30) 371,717 (55)
Japan 2,835 (7) 20,170 (3)
Other 1,554 (4) 25,240 (4)
Lifestyle factors
Smoking status — no. (%)
Current smoker 8,894 (22) 225,331 (33)
Other 31,222 (78) 449,614 (67)
Alcohol use — no./total no. (%)
Current drinker 10,177/20,447 (50) 232,476/365,375 (64)
Other 10,270/20,447 (50) 132,899/365,375 (36)
Physical activity — no./total no. (%)†
Not active 4117/8723 (47) 132,795/258,071 (51)
Active 4606/8723 (53) 125,276/258,071 (49)
Anthropometric markers
Body-mass index‡
No. with data 40,116 674,945
Mean 28±5 26±4
Systolic blood pressure
No. with data 36,434 504,516
Mean — mm Hg 144±19 135±18
Waist circumference
No. with data 10,324 127,636
Mean — cm 97±13 89±12
Waist-to-hip ratio
No. with data 10,288 127,167
Mean 0.93±0.07 0.89±0.08
Lipids
Total cholesterol
No. with data 35,016 494,678
Mean — mmol/liter 5.9±1.2 5.9±1.1
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Fasting Glucose and Mortality
Fasting glucose level was nonlinearly related to 
the risk of death (Fig. 2). Fasting glucose levels 
exceeding 100 mg per deciliter (5.6 mmol per liter) 
but not levels of 70 to 100 mg per deciliter (3.9 to 
5.6 mmol per liter) were associated with excess 
risk (Fig. 5 and 6 in the Supplementary Appendix). 
At fasting glucose levels above 100 mg per decili-
ter, hazard ratios for higher levels of glucose, as-
sessed in increments of 18 mg per deciliter (1 mmol 
per liter), were 1.05 (95% CI, 1.03 to 1.06) for can-
cer deaths, 1.13 (95% CI, 1.11 to 1.15) for vascu-
Table 1. (Continued.)
Characteristic
Diabetes 
(N = 40,116)
No Diabetes 
(N = 674,945)
Non-HDL cholesterol
No. with data 25,906 321,267
Mean — mmol/liter 4.6±1.1 4.5±1.1
HDL cholesterol
No. with data 25,928 321,537
Mean — mmol/liter 1.2±0.4 1.4±0.4
Loge triglycerides
No. with data 27,515 397,593
Mean — mmol/liter 0.5±0.6 0.3±0.5
Inflammatory markers
Fibrinogen
No. with data 12,598 162,820
Mean — μmol/liter 9.8±2.3 9.3±2.1
Loge C-reactive protein
No. with data 6,979 104,642
Mean — mg/liter 0.9±1.1 0.6±1.1
Metabolic and renal markers
Fasting glucose
No. with data 22,015 157,023
Mean — mmol/liter 8.6±3.6 5.2±0.6
Loge insulin
No. with data 6,911 53,711
Mean — pmol/liter 4.6±0.7 4.0±0.6
Glycated hemoglobin
No. with data 4,971 48,468
Mean — % 7.2±2.0 5.3±0.5
Loge estimated glomerular filtration rate§
No. with data 22,122 216,585
Mean — ml/min/1.73 m2 4.3±0.3 4.4±0.2
* Plus–minus values are means ±SD. Data are shown for the 715,061 of the 820,900 participants without known preexist-
ing cardiovascular disease at baseline and for whom there was complete information about age, sex, smoking status (cur-
rent smoker vs. any other status) and body-mass index. Information about the other characteristics in the table was not 
available for all participants. Diabetes was ascertained on the basis of self-report, medication use, fasting glucose level 
of 126 mg per deciliter (7.0 mmol per liter) or more, or a combination of these. To convert values for cholesterol to mil-
ligrams per deciliter, divide by 0.02586. To convert values for triglycerides to milligrams per deciliter, divide by 0.01129. To 
convert values for fibrinogen to grams per deciliter, divide by 29.41. To convert values for insulin to microunits per mil-
liliter,  divide by 6.945. To convert values for fasting glucose to milligrams per deciliter, divide by 0.05551. HDL denotes 
high-density lipoprotein.
† Physical activity was defined as any form of aerobic or anaerobic exercise.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Estimated glomerular filtration rate was calculated with the use of the Modification of Diet in Renal Disease equation.
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lar deaths, 1.10 (95% CI, 1.07 to 1.12) for non-
cancer, nonvascular deaths, and 1.10 (95% CI, 
1.09 to 1.11) for death from any cause, assuming 
the existence of log-linear relationships above the 
threshold of 100 mg per deciliter (although as-
sociations with cancer deaths tended to plateau at 
higher levels).
There were generally too few deaths to char-
acterize the shapes of associations of fasting 
glucose level with more specific causes of death. 
To avoid potential bias, we examined hazard 
ratios for various fasting glucose categories after 
excluding participants with a known history of 
diabetes at enrollment. As compared with the 
reference group (with a fasting glucose level of 
70 to 100 mg per deciliter), hazard ratios for 
those with a fasting glucose level of 126 mg per 
deciliter (7.0 mmol per liter) or more were 1.39 
(95% CI, 1.22 to 1.59) for cancer deaths, 1.89 (95% 
CI, 1.69 to 2.10) for vascular deaths, and 1.54 
(95% CI, 1.31 to 1.81) for noncancer, nonvascu-
lar deaths. As compared with the same reference 
group, hazard ratios for participants with im-
paired fasting glucose levels (100 to <126 mg 
per deciliter [5.6 to <7.0 mmol per liter]) were 
1.13 (95% CI, 1.06 to 1.20) for cancer deaths, 
1.17 (95% CI, 1.08 to 1.26) for vascular deaths, 
and 1.12 (95% CI, 1.07 to 1.18) for noncancer, 
nonvascular deaths; whereas hazard ratios for 
participants with fasting glucose levels less than 
70 mg per deciliter were 1.01 (95% CI, 0.93 to 1.10) 
for cancer deaths, 1.32 (95% CI, 1.12 to 1.56) for 
vascular deaths, and 1.05 (95% CI, 0.89 to 1.24) 
for noncancer, nonvascular deaths (Fig. 5 in the 
Supplementary Appendix). Among people with a 
history of diabetes at baseline, hazard ratios for 
death were higher among those who had a fast-
ing glucose level of 126 mg per deciliter or more 
as compared with those who had a level below 
126 mg per deciliter (hazard ratio, 2.16 vs. 1.51) 
(Fig. 5 in the Supplementary Appendix).
Qualitatively similar findings to those report-
ed here were observed in a range of subsidiary 
analyses, such as those that included 75,195 par-
ticipants with a history of cardiovascular disease 
at baseline (Fig. 7 in the Supplementary Appen-
dix), excluded the initial 5 years of follow-up, 
excluded current smokers (Table 5 in the Sup-
plementary Appendix), corrected for regression 
dilution in the fasting glucose level and in po-
tential confounders (Fig. 8 and Table 6 in the 
Supplementary Appendix), assessed interactions M
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with sex and age, excluded 56,766 participants 
known to be taking lipid-lowering or blood pres-
sure–lowering medication at baseline (Table 5 in 
the Supplementary Appendix), standardized glu-
cose values in studies that did not involve plas-
ma measurements, assessed fasting glucose lev-
els while ignoring a history of diabetes at 
baseline (Fig. 9 in the Supplementary Appendix), 
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Figure 1. Hazard Ratios for Death from Cancer and from Noncancer, Nonvascular Causes among Participants 
with Diabetes as Compared with Those without Diabetes at Baseline.
Panel A shows hazard ratios for deaths from cancer, and Panel B shows hazard ratios for deaths from noncancer, non-
vascular causes. With the exception of the classifications “site unspecified or other” in Panel A and “other noncan-
cer, nonvascular deaths” in Panel B, causes of death are presented in descending order according to their estimated 
hazard ratios. All analyses were stratified on the basis of study, sex, and trial group (where applicable) and adjusted 
for baseline age, smoking status (current smoker vs. any other status), and body-mass index. There was evidence of 
heterogeneity in hazard ratios among cancer sites and among the noncancer, nonvascular causes of death (P<0.001 
for both comparisons). Participants with known preexisting cardiovascular disease at baseline were excluded from all 
analy ses. The sizes of the data markers are proportional to the inverse of the variance of the loge hazard ratios. In 
Panel A, risk estimates for cancer of the colorectum were broadly similar to those for cancer at subsites (i.e., colon 
cancer vs. cancer of the rectosigmoid and anus). In Panel B, death from endocrine disorders does not include death 
coded as being due to diabetes. Other noncancer, nonvascular deaths are those that could not be attributed to a 
major organ or system. COPD denotes chronic obstructive pulmonary disease.
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focused solely on the 60 cohort studies that 
recruited participants from population registries 
or general-practice lists (Fig. 10 in the Supple-
mentary Appendix), and explored the effect of 
plausible degrees of potential misclassification 
of baseline diabetes status, new-onset diabetes, 
or attribution of cause of death (Table 7 and Fig. 
11 in the Supplementary Appendix).
On average, middle-aged adults with diabetes 
but without known vascular disease at the time 
of enrollment died about 6 years younger than 
people without diabetes (Fig. 3). At 40, 50, and 
60 years of age, men with diabetes but without a 
history of vascular disease would incur about 
6.3, 5.8, and 4.5 years of life lost, respectively. 
The corresponding years of life lost for women 
with diabetes in middle age were 6.8, 6.4, and 
5.4 years, respectively. About 58%, 9%, and 30% 
of this survival difference at 50 years of age can 
be attributed to excess vascular, cancer, and non-
cancer, nonvascular deaths, respectively.
Discussion
In addition to the excess risk of vascular disease, 
our data show that diabetes is associated with 
substantial premature mortality from several can-
cers, infectious diseases, external causes, inten-
tional self-harm, and degenerative disorders, in-
dependent of several major risk factors. Our 
results suggest that, on average, a 50-year old 
with diabetes but with no history of vascular dis-
ease is about 6 years younger at the time of death 
than a counterpart without diabetes; for compari-
son, the reduction in life expectancy from long-
term cigarette smoking is about 10 years.20 About 
40% of the years of life lost from diabetes can be 
attributed to nonvascular conditions, including 
about 10% attributable to death from cancer.
We have also found that there are generally 
continuous associations between fasting glucose 
levels greater than 100 mg per deciliter and risk 
of death, supporting the view that hyperglycemia 
(or some factor closely related to it) may be di-
rectly relevant. This possibility is also consistent 
with substantial attenuation observed in hazard 
ratios for death from diabetes after adjustment 
for markers of glycemia (though interpretation 
of such analyses is complicated because glucose 
levels are used to define diabetes status). In con-
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Figure 2. Hazard Ratios for Major Causes of Death, According to Baseline Levels of Fasting Glucose.
History of diabetes at baseline was defined according to a self-reported history of diabetes or treatment for diabetes. Glucose levels for 
participants without a known history of diabetes at baseline were classified as less than 4.0, 4.0 to less than 4.5, 4.5 to less than 5.0, 5.0 to 
less than 5.5, 5.5 to less than 6.0, 6.0 to less than 6.5, 6.5 to less than 7.0, 7.0 to less than 7.5, and 7.5 mmol per liter or higher. Hazard 
ratios were plotted against the mean fasting glucose level in each group (reference category, 5.0 to <5.5 mmol per liter). The sizes of the 
data markers are proportional to the inverse of the variance of the loge hazard ratios. All analyses were stratified or adjusted for sex and 
adjusted for baseline age, smoking status (current smoker vs. any other status), and body-mass index. Participants with known preexist-
ing cardiovascular disease at baseline were excluded from all analyses. To convert values for fasting glucose to milligrams per deciliter, 
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trast, we did not observe appreciable alteration in 
the associations between diabetes and mortality 
after adjustment for several other risk factors (e.g., 
systolic blood pressure, measures of adiposity, 
inflammation biomarkers, insulin, or renal func-
tion), even after using serial measurements to 
adjust for their long-term average levels. These 
findings reduce the likelihood that such risk fac-
tors are major mediators of the excess risk of 
death associated with diabetes in our study.
Our study indicates that diabetes is moder-
ately associated with death from cancers of the 
liver, pancreas, ovary, colorectum, lung, bladder, 
and breast (although, because multiple disease 
outcomes were studied, any marginally significant 
findings should be evaluated further). Although 
causality has not been established for these asso-
ciations, systemic21 and local22,23 factors have 
been proposed to explain them. For pancreatic 
cancer, however, diabetes can be a consequence 
of the cancer, rather than a cause,24 although 
the exclusion of initial follow-up data did not 
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weaken the hazard ratios in this study. In con-
trast with some previous studies of the inci-
dence of prostate cancer, however, we did not 
find a significant inverse association of diabetes 
with the incidence of death from prostate can-
cer, although our confidence intervals were com-
patible with the risk estimates reported previ-
ously.25
Aside from cancers, we observed strong posi-
tive associations of diabetes with deaths from 
renal and digestive diseases and infectious dis-
eases. These results may reflect associated ne-
phropathy, fatty liver disease, and suppression of 
cellular immunity, respectively.26-28 Furthermore, 
diabetes is associated with death from injuries, 
which could be related to end-organ complica-
tions such as neuropathy and eye disease or to 
episodes of hypoglycemia. Associations observed 
between diabetes and deaths due to mental and 
neurologic diseases should be studied further, 
including disaggregation into more specific con-
ditions and investigation of the possible link be-
tween diabetes and the onset of depression,29 
particularly since we found that among people 
with diabetes there was a substantial excess of 
deaths due to intentional self-harm. Collectively, 
therefore, our findings broaden and intensify 
the need for efforts to prevent and understand 
diabetes and encourage detailed study of a broad-
er range of disease outcomes than has been 
customary in randomized trials of diabetes pre-
vention and treatment.30 These results also re-
inforce the need for people with diabetes to 
consider cancer screening appropriate for their 
age and sex.
Our study has several strengths. These include 
the large sample size (over 123,000 deaths re-
corded during more than 12 million person-years 
at risk), standardized approaches to adjustment 
for several potential confounding factors, serial 
assessment of risk factors in 331,515 participants, 
an extended follow-up period, and information 
about cause-specific deaths from a variety of 
conditions. Furthermore, we studied several fac-
tors proposed to mediate associations of diabe-
tes and cancer.31
The generalizability of our findings to popu-
lations in economically developed Western coun-
tries is supported by broadly consistent results 
across 97 prospective cohorts in 25 countries. 
Even though the 6% overall prevalence of diabe-
tes in our study was somewhat lower than the 
prevalence currently reported for some Western 
populations, this difference would not have influ-
enced hazard ratios. To enhance the validity of 
our findings, we conducted a range of sensitiv-
ity analyses, including a focus on population-
based cohorts, adjustment for several major risk 
factors, and exclusion of the initial years of the 
follow-up period. We investigated mortality rather 
than the incidence of nonfatal disease, which 
should have reduced the likelihood of finding 
artifactual associations due to preferential diag-
nosis of certain conditions in people with diabe-
tes. Indeed, we observed qualitatively similar 
results among people with no history of diabetes 
but a fasting glucose level of 126 mg per deciliter 
or more and among people with a history of 
diabetes at baseline. However, our study cannot 
determine whether diabetes might increase the 
incidence of such diseases or reduce survival (or 
both) among persons with such illnesses.
Despite the strengths of our study, residual 
bias could persist owing to unmeasured or im-
precisely measured potential confounding factors 
(e.g., dietary intake and physical activity, respec-
tively). Certain glucose-lowering agents have been 
reported to increase32 or decrease33 the risk of 
cancer, but our observational study cannot reli-
ably address these questions. Because our study 
did not include comprehensive recording of use 
of aspirin (an agent that is known to prevent 
vascular disease and may also prevent colorectal 
cancer34,35), we may have underestimated the 
hazard ratios for death from colorectal cancer. 
Although our data suggest that hazard ratios for 
death in patients with diabetes may have de-
clined somewhat in recent decades,36 this find-
ing may be subject to confounding, because 
cohort studies initiated in earlier decades may 
differ in several ways from more recent cohort 
studies. Were the decline to be confirmed, how-
ever, then it would imply that our study has 
slightly overestimated the contemporary effect 
of diabetes on death. Future studies are war-
ranted to investigate additional (and potentially 
more specific) risk factors that may link diabetes 
and chronic diseases, to study non-Western popu-
lations,37 and to explain associations observed 
between very low glucose levels and vascular 
death in people without diabetes.
In conclusion, in addition to vascular disease, 
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diabetes is associated with substantial premature 
death from several cancers, infectious diseases, 
external causes, intentional self-harm, and degen-
erative disorders, independent of major risk fac-
tors. These findings highlight the need to better 
understand and prevent the multisystem conse-
quences of diabetes.
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